The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells

ConclusionsOur data indicate that FOXO3a activation is a crucial event in the response of GBM cells to EGFR inhibition, suggesting that FOXO3a may serve as an actionable therapeutic target that can be modulated using FDA-approved drugs.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research